Chronic Lymphocytic Leukemia Clinical Trials and Research

Short placeholder heading

Clinical Trials Questions?

877-338-7425

Our goal is to have a clinical trial option available for patients at every stage of disease. We offer a range of clinical trials for newly-diagnosed CLL, relapsed/refractory CLL, as well as Richter's syndrome, a condition where CLL turns into an aggressive form of lymphoma.

Featured Clinical Trials

Newly-Diagnosed CLL

22-303: MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Principal Investigator: Matthew Davids, MD, MMSc

Relapsed/Refractory CLL

21-279: A phase 2 trial of zanubrutinib and venetoclax in previously treated CLL/SLL patients
Principal Investigator: Inhye Ahn, MD

20-415: SAVE (Safe Accelerated Venetoclax Escalation): A phase 1b study of venetoclax monotherapy with accelerated dose ramp-up in patients with CLL
Principal Investigator: Jennifer Crombie, MD

18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
Principal Investigator: Matthew Davids, MD, MMSc

Richter’s Syndrome

23-429: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin or atezolizumab in Richter's transformation
Principal Investigator: Matthew Davids, MD, MMSc

18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic lymphoma or small lymphocytic lymphoma (includes Richter's syndrome cohort)
Principal Investigator: Matthew Davids, MD, MMSc

16-596: CRC043: A phase 2 study of venetoclax in combination with R-CHOP for the therapy of patients with Richter’s syndrome
Principal Investigator: Matthew Davids, MD, MMSc

Learn more about clinical trials for CLL patients.

Translational Science

Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:

  • Examining genetic material of a variety of CLLs in order to identify genetic changes that cause CLL
  • Studying functional response of CLL cells to novel agent therapies to predict response to therapy and identify novel resistance mechanisms
  • Providing CLL samples to a large network of collaborators who are working to better understand how CLL develops and how we can best target it with the goal of finding a cure

Matthew Davids, MD, MMSc, on Advances in CLL Treatment

Matthew Davids, MD, MMSc, of Dana-Farber’s Center for Chronic Lymphocytic Leukemia, shares updates on advances in treating newly-diagnosed and relapsed CLL. New approaches include ibrutinib + FCR for younger, newly-diagnosed patients and a combination of rituximab and venetoclax for relapsed patients.

Genetic Study of Familial Chronic Lymphocytic Leukemia and Lymphomas

Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have CLL, lymphoma, or a lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Conner Shaughnessy.

Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma

Research Labs

Jennifer Brown Lab
Matthew Davids Lab
Catherine Wu Lab

CLL Research News

Catherine Wu, MD, comments on her latest research on CLL, including the impact of mutated SF3B1 on CLL-associated pathways.